Drugs / recombinant interferon alfa
recombinant interferon alfa
also known as
interferon alfa · IFN-A · interferon alfa-2b · interferon alpha · NSC-377523 · alpha-interferon · IFN-A2b · IFN-alpha · +4 more
Trials 60
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT00082719 | Dec 2003 → Jan 2015 | urethra cancer, urinary bladder cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00045370 | Apr 2002 → Nov 2003 | kidney cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00004244 | Mar 2000 → Jul 2005 | cutaneous melanoma, kidney cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00003451 | Aug 1998 → Dec 2001 | cancer of unknown primary site, leukemia, myelodysplastic syndrome, myeloproliferative neoplasm +2 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00003263 | Aug 1996 → Dec 1999 | malignant mesothelioma | Fox Chase Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00002734 | Mar 1996 → Apr 2001 | ovarian cancer, primary peritoneal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 238 trials | ||||||
| Phase 2 | NCT00262951 | Jan 2005 → Apr 2011 | pancreatic ductal adenocarcinoma | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 2 | NCT00085436 | Dec 2003 → Oct 2009 | kidney cancer | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00059813 | Aug 2003 → Jun 2005 | renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00041327 | Oct 2002 → Dec 2006 | lymphoma | AIDS Malignancy Consortium | Completed | No outcome recorded |
| Phase 2 | NCT00068575 | May 2002 → Dec 2010 | pancreatic adenocarcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00045422 | Apr 2002 → Oct 2003 | leukemia | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00026520 | Nov 2001 → Apr 2006 | cutaneous melanoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00026221 | Nov 2001 → Nov 2013 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00026416 | Oct 2001 → ? | sarcoma | Herbert Irving Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 2 | NCT00015912 | Jul 2001 → Sep 2003 | B-cell non-Hodgkin lymphoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00015847 | Apr 2001 → May 2011 | leukemia | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00027664 | Feb 2001 → ? | kidney cancer | Cancer Research UK | Unknown | No outcome recorded |
| Phase 2 | NCT00006006 | Aug 2000 → Mar 2005 | hepatocellular carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00006244 | Feb 2000 → Apr 2016 | plasma cell myeloma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00005948 | Jan 2000 → Oct 2001 | leukemia | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00014092 | Dec 1999 → Dec 2003 | cutaneous melanoma | Saint Francis Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00004905 | Oct 1999 → Sep 2004 | leukemia | Loyola University | Completed | No outcome recorded |
| Phase 2 | NCT00004897 | Oct 1999 → Jul 2007 | esophageal cancer | Northwestern University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00007995 | Jul 1999 → Nov 2007 | plasma cell myeloma | Herbert Irving Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00004122 | Jul 1999 → Apr 2001 | urinary bladder cancer | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00003715 | Dec 1998 → ? | cutaneous melanoma | AVAX Technologies | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00003664 | Oct 1998 → ? | kidney cancer | Cancer Biotherapy Research Group | Unknown | No outcome recorded |
| Phase 2 | NCT00003416 | Sep 1998 → Aug 2000 | lymphoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00011934 | May 1998 → Aug 2002 | leukemia | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT00003408 | Apr 1998 → Mar 2000 | breast cancer, gestational trophoblastic neoplasm, kidney cancer, leukemia +7 | Cancer Treatment Centers of America | Completed | No outcome recorded |
| Phase 2 | NCT00003405 | Apr 1998 → Apr 1999 | leukemia | Rush University Medical Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00003239 | Mar 1998 → Oct 2001 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00019474 | Mar 1998 → Aug 2000 | carcinoid tumor, extrahepatic bile duct carcinoma, gastric cancer, malignant pancreatic neoplasm +1 | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00003561 | Feb 1998 → Oct 2001 | leukemia | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 2 | NCT00003195 | Dec 1997 → Nov 2000 | plasma cell myeloma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002965 | Jan 1997 → Mar 2003 | central nervous system neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002849 | Nov 1996 → Dec 1998 | plasma cell myeloma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00002733 | Jan 1996 → Jan 2000 | cutaneous melanoma, kidney cancer | Hoag Memorial Hospital Presbyterian | Completed | No outcome recorded |
| Phase 2 | NCT00002657 | May 1995 → Nov 2003 | plasma cell neoplasm | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00002621 | Dec 1994 → Jul 2002 | childhood malignant neoplasm, leukemia, lymphoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00002574 | Sep 1994 → Jun 2001 | leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00002829 | Feb 1994 → Apr 2002 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00002506 | Aug 1992 → Jan 1996 | cervical cancer, esophageal cancer, head and neck cancer, lung cancer +2 | Hoag Memorial Hospital Presbyterian | Completed | No outcome recorded |
| Phase 316 trials · 1 met primary · 3 missed | ||||||
| Phase 3 | NCT00054561 | Nov 2003 → Dec 2004 | head and neck cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00053820 | Jul 2002 → Dec 2006 | renal cell carcinoma | Medical Research Council | Completed | Missed primary |
| Phase 3 | NCT00028886 | Mar 2001 → ? | plasma cell myeloma | Commissie Voor Klinisch Toegepast Onderzoek | Unknown | No outcome recorded |
| Phase 3 | NCT00016887 | Dec 2000 → ? | lymphoma | German Low Grade Lymphoma Study Group | Unknown | No outcome recorded |
| Phase 3 | NCT00006343 | Jun 2000 → Mar 2007 | leukemia | Novartis | Completed | Met primary |
| Phase 3 | NCT00447356 | Jan 2000 → ? | cutaneous melanoma | Hackensack Meridian Health | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00004196 | Oct 1999 → Oct 2004 | cutaneous melanoma | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 3 | NCT00053807 | Feb 1998 → Jan 2004 | renal cell carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00003027 | Nov 1997 → Jul 2007 | cutaneous melanoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00025402 | Jul 1997 → ? | leukemia | III. Medizinische Klinik Mannheim | Unknown | No outcome recorded |
| Phase 3 | NCT00002767 | Jan 1996 → ? | cutaneous melanoma | GlaxoSmithKline | Unknown | No outcome recorded |
| Phase 3 | NCT00002882 | Nov 1995 → Aug 2003 | melanoma, skin cancer | M.D. Anderson Cancer Center | Completed | Missed primary |
| Phase 3 | NCT00003924 | Oct 1995 → ? | lymphoma | Lymphoma Study Association | Unknown | No outcome recorded |
| Phase 3 | NCT00002548 | Jan 1994 → Oct 2003 | plasma cell myeloma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00003639 | Nov 1993 → ? | lymphoma | Scotland and Newcastle Lymphoma Group | Unknown | No outcome recorded |
| Phase 3 | NCT00416871 | ? → Feb 2006 | kidney cancer | Centre Leon Berard | Completed | Missed primary |
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT00016042 Background | Jan 2001 → ? | colorectal cancer, kidney cancer | St. Luke's Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00005986 Background | Aug 2000 → Sep 2004 | leukemia | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 2 | NCT00002773 Background | May 1996 → Apr 2004 | pancreatic adenocarcinoma | St. Vincent Medical Center - Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT00002475 Background | Apr 1991 → Dec 2007 | breast cancer, colorectal cancer, kidney cancer, lung cancer +2 | St. Vincent Medical Center - Los Angeles | Completed | No outcome recorded |
| Phase 3 | NCT00002835 Background | Oct 1995 → Feb 2004 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00002599 Background | Sep 1994 → ? | plasma cell myeloma | Medical Research Council | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-04-23 | Zydus Lifesciences Limited | Zydus receives Emergency Use Approval from DCGI for the use of Pegylated Interferon alpha-2b, Virafin in treating moderate COVID-19 infection in adults zyduslife.com ↗ |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 70 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant interferon alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006343 ↗ |
| Known as | alpha-interferon | “followed by maintenance with alpha-interferon (arm A) or thalidomide 50 mg daily (arm B).” PMID 19880501 ↗ Oct 2009 |
| Known as | IFN-A | “with Interferon alpha (Schering or Hoffmann-La Roche), IFN-A, NSC-377523 or NSC-367982.” NCT00002506 ↗6“allogeneic melanoma vaccine plus interferon alfa-2b (IFN-A) vs. IFN-A alone” NCT00002767 ↗ “Patients receive interferon alfa (IFN-A) subcutaneously 3 times a week.” NCT00045370 ↗ “Patients receive interferon alfa (IFN-A) subcutaneously (SQ) daily.” NCT00006343 ↗ “interferon alfa (IFN-A) subcutaneously once daily or 3 times weekly” NCT00015847 ↗ “Interferon alfa (Schering), IFN-A, NSC-377523” NCT00002574 ↗ “interferon alfa (IFN-A)” NCT00002733 ↗ |
| Known as | IFN-A2b | “interferon alfa 2b (IFN-A2b) subcutaneously three times a week” NCT00003263 ↗ |
| Known as | IFN-alpha | “In combination with IFN-alpha in selected, good prognosis metastatic renal cell carcinoma patients, i.v. IL-2 offers no significant advantage over s.c. IL-2 and induces higher toxicity.” PMID 18794104 ↗ Sep 2008 |
| Known as | IFN-α | “interferon alfa (IFN-α) subcutaneously (SC) three times weekly” NCT00416871 ↗ |
| Known as | INF alpha | “Recombinant Interferon Alfa (INF alpha)” NCT00002965 ↗ |
| Known as | interferon alfa | “Patients receive chemo/immunotherapy comprising fluorouracil IV continuously over 24 hours on day 13 and GM-CSF and interferon alfa SC on days 17, 19, 21, 24, 26, and 28.” NCT00016042 ↗8“Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma” PMID 20153039 ↗ Feb 2010 “Patients receive maintenance therapy with interferon alfa SC 3 times weekly until progression or after 3 months if no partial response.” NCT00028886 ↗ “receive subcutaneous interferon alfa injections 3 times a week for 5 years or until disease progression, relapse, or toxicity.” NCT00003416 ↗ “Patients receive interferon alfa (IFN-A) subcutaneously (SQ) daily.” NCT00006343 ↗ “interferon alfa (IFN-A) subcutaneously once daily or 3 times weekly” NCT00015847 ↗ “interferon alfa (IFN-α) subcutaneously (SC) three times weekly” NCT00416871 ↗ “Interferon alfa (Schering), IFN-A, NSC-377523” NCT00002574 ↗ “interferon alfa (IFN-A)” NCT00002733 ↗ |
| Known as | interferon alfa-2a | “Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma” PMID 20153039 ↗ Feb 2010 |
| Known as | interferon alfa-2b | “allogeneic melanoma vaccine plus interferon alfa-2b (IFN-A) vs. IFN-A alone” NCT00002767 ↗2“interferon alfa 2b (IFN-A2b) subcutaneously three times a week” NCT00003263 ↗ “interferon alfa-2b as postsurgical adjuvant therapy” NCT00003715 ↗ |
| Known as | interferon alpha | “Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma” NCT00053820 ↗2“with Interferon alpha (Schering or Hoffmann-La Roche), IFN-A, NSC-377523 or NSC-367982.” NCT00002506 ↗ “standard regimen of interferon-alpha plus cytarabine” PMID 19648168 ↗ Jul 2009 |
| Known as | NSC-367982 | “with Interferon alpha (Schering or Hoffmann-La Roche), IFN-A, NSC-377523 or NSC-367982.” NCT00002506 ↗ |
| Known as | NSC-377523 | “with Interferon alpha (Schering or Hoffmann-La Roche), IFN-A, NSC-377523 or NSC-367982.” NCT00002506 ↗1“Interferon alfa (Schering), IFN-A, NSC-377523” NCT00002574 ↗ |
| Action | Inhibit | “Interferon alfa may interfere with the growth of the cancer cells.” NCT00003416 ↗ |
| Modality | Protein / enzyme biologic | “recombinant interferon alfa” NCT00002475 ↗ |
| Route | Subcutaneous | “daily subcutaneous interferon alpha” NCT00002506 ↗ |